Given the global urgency of the COVID-19 pandemic, Microsoft's AI for Health program has stepped in to support the development and potential deployment of Vaxine's COVAX-19 vaccine with a philanthropic grant.
Aug 24, 2020
0
10
With research laboratories around the world racing to develop a coronavirus vaccine, a unique challenge has emerged: how to balance intellectual property rights with serving the public good.
May 29, 2020
0
4
The coronavirus has ground social, economic and educational exchanges to a halt around the world. For now, public health officials are relying on tools like social distancing to minimize the harm of the virus, but in the ...
Mar 27, 2020
0
3
A team of researchers at the University of Georgia are developing and testing new vaccines and immunotherapies to combat the novel coronavirus that has infected hundreds of thousands across the world.
Mar 25, 2020
0
3
Professor John Whitelock is improving the smarts of antibodies and sending them into the extracellular area to outwit those clever cancer cells.
Oct 1, 2019
0
4
One of the main impediments in partnerships between the AI companies and biotechnology companies is contracting. Legal contracts for target identification and small molecule generation can be incredibly complex, especially ...
Jul 23, 2019
0
1
An antibody that targets and is taken up only by certain types of cancer cells has been developed by A*STAR researchers. Combining this antibody with an anticancer drug could lead to a new treatment for some types of breast ...
Jan 15, 2019
0
13
Recent announcements by two biotechnology companies have stoked fears that designer babies could soon be an option for those who can afford to pick and choose which features they want for their offspring. The companies, MyOme ...
In late July there were reports in the media from a conference in Chicago about Alzheimer's disease. The focus of journalists' attention was a new study of how the progression of the disease is affected by the BAN2401 antibody, ...
Oct 19, 2018
0
3
Juno Therapeutics and its CEO, Hans E. Bishop, are being named in a lawsuit over whether the biotechnology company misled investors about the death of a patient in a key study involving its drug intended to treat leukemia.
Jul 13, 2016
0
0
